The market for expression arrays is often characterized as mature, a slow-growth sector where Affymetrix and Agilent Technologies dominate, and the only options are to get out — like GE Healthcare has done — or to work hard to steal market share from the juggernauts, which is the path Illumina has chosen.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.